PDCD1 and neoplasm: In conclusion, this research clearly indicates that m7G methylation modification patterns were correlated remarkably with tumor immunophenotype and response to anti-PD-1/L1 immunotherapy and that the developed m7G modification profile will help predict response to anti-PD-1/L1 immunotherapy as well as in PD-1/L1 immunotherapy.